BioInvent International AB (publ)
BOVNF
Get informed when a big investor buys or sells
+ FollowMarket Cap$216.4M
Close$
Share Statistics
| Market cap | $216.40 Million |
|---|---|
| Enterprise Value | $-66,164,322.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.07 |
| Beta | 0.02 |
| Outstanding Shares | 65,804,362 |
Return
| Return on Equity | -157.75% |
|---|---|
| Return on Assets | -118.08% |
| Return on Invested Capital | -152.80% |
Valuation & Multiples
| P/E Ratio | -3.07 |
|---|---|
| PEG | 0.74 |
| Price to Sales | - |
| Price to Book Ratio | 0.82 |
| Enterprise Value to Revenue | 67.38 |
| Enterprise Value to EBIT | -4.38 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$1.11 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$796,855
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioInvent International AB (publ)
108 employees
CEO: Martin Welschof BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and...